TEMPESTAS

The microbial effect of inhaled steroids in severe COPD patients with associated bronchiectasis

The aim of the study is to investigate whether inhaled steroids along with other types of inhaler, that open the airways, can affect the amount and type of bacteria in the airways. This will be assessed over 1 year in patients with GOLD Stage D COPD and a co-diagnosis of bronchiectasis.

 

TEMPESTAS LOGO

Chief Investigator (UK): Dr Gourab Choudhury

Number and location of participating sites (by region/country): 3 UK Sites

EudraCT number: 2022-000524-38

ISRCTN number:  15449782

 

Funder: Glaxo SmithKline

 

Start and End date 

of grant award: 01 September 2021 to 29 February 2024

of recruitment: May 2022 to January 2023

 

Current status: In set up

 

UK GDPR Privacy Statement: If you have participated in this study and would like to read how it complies with UK GDPR, please read this document.

TEMPESTAS GDRP STATEMENT (429.78 KB / PDF)

 

UK Sponsor: University of Edinburgh & NHS Lothian ACCORD

 

Chief Investigator: Dr Gourab Choudhury, Royal Infirmary of Edinburgh, Little France, Edinburgh, EH16 4TJ    

 

Trial Management Team:  TEMPESTAS.Trial@ed.ac.uk

 

ECTU Involvement: Trial Management (UK only)

(UKCRC)

This article was published on